Gender-related aspects in chronic myeloid leukemia (CML) have not been studied well. We therefore analyzed 856 patients with Ph/BCR-ABL-positive CML from the German randomized CML-studies I (interferon a (IFN) vs hydroxyurea (HU) vs busulfan) and II (IFN þ HU vs HU alone). The median observation time was 8.6 years. A total of 503 patients (59%) were male. Female patients were older (51 vs 46 years; Po0.0001), presented with lower hemoglobin (11.7 vs 12.5 g/dl; Po0.0001), higher platelet counts (459 vs 355 Â 10 9 /l; Po0.0001), smaller spleen size (3 vs 4 cm below costal margin; P ¼ 0.0097), a lower rate of additional cytogenetic aberrations (9 vs 15%; P ¼ 0.018) and a less favorable risk profile (P ¼ 0.036). The transplantation rate was 14% for female (n ¼ 48) and 22% for male patients (n ¼ 113). Median survival was longer in female patients (58 vs 49 months; P ¼ 0.035) mainly attributable to better survival in the low-and intermediate-risk groups and, independent from risk groups, in the HU group. These results were confirmed by matched-pair analyses based on German population data (n ¼ 496, 59 vs 45 months; P ¼ 0.0006). This is the first analysis of gender aspects in CML using randomized trials. It demonstrates the relevance of analyses of gender differences in CML and in malignant disease at large.
Introduction
Gender-specific differences in signs and symptoms at presentation and in outcome have been increasingly realized in various diseases. Recent examples are outcome in ischemic and nonischemic heart disease [1] [2] [3] and in solid neoplastic disorders such as malignant melanoma, [4] [5] [6] non-small-cell lung cancer treated with gefitinib and tipifarnib, [7] [8] [9] surgically treated colorectal cancer, 10 esophageal carcinoma, 11 renal cell carcinoma 12 and soft tissue sarcoma. 13, 14 Gender differences in survival have been reported also in hematological malignancies such as Hodgkin's disease, 15 acute myeloid leukemia, 16 and childhood acute lymphoblastic leukemia. 17 Gender aspects have become an objective of health politics and are also addressed within the German and European leukemia networks. 18 Differences in gender-specific incidence and prognosis have long been recognized also in chronic myeloid leukemia (CML) . 19 Male predominance was demonstrated in clinical trials, 20, 21 and the Sokal score for younger patients (o45 years old) has identified female sex as a favorable prognostic factor. 22 These findings, however, never have been followed up systematically, and gender-associated differences have not been studied well in CML. We therefore used 856 well-characterized patients from the German CML-studies I and II 20, 21 to analyze possible gender differences in signs, symptoms, and prognostic factors at diagnosis, remission variables, duration of chronic phase and survival according to treatment in a systematic fashion.
Patients and methods

Patients and therapy
A total of 856 Ph and/or BCR-ABL-positive CML patients in chronic phase were derived from two consecutive, randomized trials (German CML-studies I (HU vs busulfan (Bu) vs IFN) and II (IFN þ HU vs HU alone), recruitment from 7/1983 through 12/ 1994) representing all patients from trials I and II. 20, 21 The recruited patients represent about 10% of CML patients in Germany (West-Germany until 1990) during the recruitment period. In both trials inclusion criteria were newly diagnosed chronic phase CML, no prior therapy and treatment requirement as defined by the presence of at least one of the following criteria: unexplained fatigue, weight loss of more than 10% body weight in 6 months, fever exceeding 38.51C on five consecutive days, organomegaly-related symptoms, WBC count of more than 50 Â 10 9 /l or platelet count of more than 1 Â 10 12 /l at the time of recruitment. All patients with newly diagnosed CML in chronic phase and no pretreatment were recruited. Ph/ BCR-ABL-negative patients were evaluated separately. A total of 130 patients were not randomized due to exclusion criteria, mostly lack of consent, no treatment requirement, pretreatment or no chronic phase. 20, 21 Patients were randomized to receive either Bu, HU or IFN alone or in combination with HU. Of the 856 patients, 188 were treated with Bu, 308 with HU and 360 with IFN-based therapy. Detailed descriptions of the protocols of CML-studies I and II were published previously. 20, 21 Prognostic groups were determined according to the score by Hasford et al.
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Response criteria
Complete hematologic remission was defined as normal WBC counts with normal differential (WBC count less than 10 Â 10 9 /l, bands and metamyelocytes p5%), normal platelet count, no CML-related symptoms and normal spleen size (not palpable or 12 cm maximum diameter). A partial hematologic remission was defined as a more than 50% decrease of WBC count or a WBC count p20 Â 10 9 /l). For cytogenetic analyses, 25 metaphases were analyzed whenever possible. Karyotypes with less than five metaphases were excluded from the analysis. If five to 10 metaphases were analyzed, the data were not used unless they fitted in a pattern obtained by previous or subsequent analyses or by concomitant quantitative reverse transcriptase-polymerase chain reactions (RT-PCR) of BCR-ABL transcripts according to published procedures. 24, 25 Complete cytogenetic remission was defined as absence of any Ph-positive metaphase, partial, minor and minimal responses as decreases of Ph-positive cells to 1-34%, 35-65%, and 66-95%, respectively.
Adverse effects and follow-up
Adverse effects were reported according to the WHO toxicity criteria in four grades: mild, moderate, severe, life threatening. Baseline 'adverse effects' recorded at the time of diagnosis were subtracted. Pretherapeutic diagnostic evaluation consisted of history, physical examination, complete blood cell count including reticulocytes, alkaline leukocyte phosphatase, serum lactate dehydrogenase (LDH), ALAT, ASAT, cytogenetics, molecular genetic analysis, and bone marrow cytology and histology.
Investigations at 6-monthly intervals included inquiry about symptoms (fever, fatigue, adverse drug effects), physical examination (spleen size, extramedullary manifestations, weight), complete blood cell count, LDH, ALAT, ASAT, drug dosages and cytogenetics in the IFN arm; investigations at 12 months intervals included cytogenetics and bone marrow cytology and histology. Additional investigations were documented at the end of chronic phase, onset of blast crisis and death.
Statistics
Adverse events were described in accordance with the treatment the patients had actually received. All other analyses were performed following the intention-to-treat principle. As formal significance level, a ¼ 0.05 was chosen. Patients' data at baseline were compared using w 2 test, Student's t test or the Mann-Whitney test, as appropriate. Survival time and duration of chronic phase were censored at the time of allogeneic SCT for all patients transplanted in first chronic phase. Survival probabilities were estimated according to Kaplan and Meier. 26 The corresponding test statistic was the log-rank test. Since treatment and Hasford's risk group are known to have statistically significant influence on survival, also log-rank statistics adjusted for these factors were calculated. If no difference in the level of significance was observed, in the following, only the P-value of the unadjusted log-rank test is given. The Cox regression model was used to analyze the prognostic influence of baseline factors on survival. 27 Additional matched-pair analyses were carried out to take into account the general longevity of women. Female patients were matched to male patients according to age-and gender-related general life expectancy at diagnosis (categorical 5-year intervals based on German population data from the 'Institut fü r Bevö lkerungsforschung und Sozialpolitik', University Bielefeld, Germany), risk group, therapy, CML trial (I or II) and SCT in chronic phase.
Ethics
The protocols followed the Declaration of Helsinki and were approved by the ethics committee of the Fakultät fü r Klinische Medizin Mannheim of the University Heidelberg and by local ethics committees. Informed consent was obtained from all patients.
Results
Patients' characteristics at diagnosis
Patients' characteristics at diagnosis according to gender are shown in Table 1 . Female patients were older at diagnosis than male patients (51 vs 46 years; Po0.0001) and presented with lower hemoglobin (11.7 vs 12.5 g/dl; Po0.0001), higher platelet counts (459 vs 355 Â 10 9 /l; Po0.0001), smaller spleen size (3 vs 4 cm below costal margin; Po0.01) and a lower rate of additional chromosomal aberrations (9 vs 15%; P ¼ 0.018). Women had a less favorable risk group distribution at the time of diagnosis than men (P ¼ 0.036). No differences were observed in WBC counts, differential, bone marrow blasts, promyelocytes, basophils, eosinophils and disease-related signs and symptoms (fatigue, organomegaly-related symptoms, weight loss, fever, Karnofsky index and extramedullary involvement).
The age distribution according to gender is shown in Figure 1 . The age groups below 55 years show male predominance. Women, probably as a consequence of their better longevity, have a higher incidence in the age group above 55 years. Therefore, the fraction of women is higher in the high-risk group, since age is an important prognostic factor both in the Sokal and the Hasford score (Supplementary Figure on website) .
Time dependent variables
The median observation time was 8.6. years for living patients (n ¼ 81: female n ¼ 36; male n ¼ 45) and 3.4 years for all patients. Hematologic remission rates through all treatments were similar for both sexes as were cytogenetic response rates in IFN-based therapy (Table 2) . Adverse effects in IFN-based therapy were similar in frequency and severity (Supplementary Table on website). A total of 161 patients received allogeneic SCT in first chronic phase. More men (n ¼ 113) than women (n ¼ 48) were transplanted (Supplementary Figure on website) . The lower transplantation rate in female patients may in part be due to the higher age of female patients at diagnosis (compare Table 1 ). 
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Differences in survival and duration of chronic phase
Women had a significantly longer survival than men as depicted in Figure 2a for all treatments. The median survival was 58 months for female and 49 months for male patients (P ¼ 0.035). The better survival of female patients was especially marked in the low (88 vs 59 months, P ¼ 0.040) and the intermediate-risk groups (58 vs 51 months, P ¼ 0.021) (Figure 3a 
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Figure 1 Age distribution according to gender. However, the corresponding matched-pair analysis within a much larger data set of IFN-treated patients from several trials and countries 23 could not confirm any influence of gender on survival in this group (P40.4, data not shown).
Causes of death
In total, 614 patients died, 161 were transplanted in chronic phase and censored, and 81 were alive at the time of evaluation. The main cause of death was disease progression to blast crisis (Table 3) . Rates of death due to blast crisis were similar in women and men. In HU-treated patients, death due to blast crisis was more frequent in men than in women (77 vs 70%, data not shown). Death due to CML-independent causes was more likely in female than in male patients (14 vs 10%).
Discussion
Two observations reported in this paper are particularly worth noting: (1) Female CML patients survived significantly longer than male patients mainly attributable to better survival in the low-and intermediate-risk groups, and independent from the risk groups if treated by HU. This survival advantage is observed also after adjustment for the general longevity of women by matched-pair analysis. This is a useful baseline information for future survival analyses of newer treatments such as imatinib and beyond. (2) Although female patients have a worse risk profile primarily due to their higher age, they survived longer. The latter observation might be a trial-related artefact in favor of older women due to the reluctance to randomize women of child-bearing age. CML in the elderly has recently been detailed in a long-term evaluation. 28 In spite of the good sample size of the cohort and confirmation by matched-pair analyses, the observation of a survival advantage for female CML patients has to be regarded as hypothesis-generating only. In a pool of 1400 IFN-treated patients, 23 no influence of gender on survival could be detected raising the question whether the life-prolonging effect of IFN might be more pronounced in men. Consequently, other cohorts have to be prospectively analyzed for the correlation of gender with survival in the future, for example, in trials with imatinib such as CML study IV. 29 The higher age of the female group, and a greater reluctance of women to undergo high-risk procedures might have resulted in a lower rate of transplantations.
The situation in CML is in line with gender differences in survival observed in other cancers and hematologic malignancies. 4, 5, [7] [8] [9] [10] [11] [13] [14] [15] [16] [17] 30 Reports of a male survival advantage in cancer patients are rare. 31 The better survival of women with malignant diseases might just reflect their better general longevity, an earlier disease stage at diagnosis or a more favorable risk profile. Some authors hypothesized the hormonal status to have an impact on the course of neoplastic disease. 6 Others highlighted genetic and environmental factors as possible 
